Print Page | Contact Us | Report Abuse | Sign In | Join
News & Press: Latest

COVID-19 Treatments Must Work for Communities of Color

Thursday, June 11, 2020   (1 Comments)
Share |

Lack of Diversity in Clinical Trials Requires Greater Effort from Regulators, Industry

Washington, D.C. - Thursday, June 11, The Alliance of Multicultural Physicians (the Alliance) urged FDA Commissioner Stephen Hahn and members of Congress in a letter to make diversity in clinical trials a greater priority in order to address disparities in COVID-19 cases and deaths in racial/ethnic minority communities, and to address a longstanding lack of diverse participation in clinical trials. The letter came within weeks of an FDA stakeholder call on COVID-19 with the Alliance and other medical groups that advocate for vulnerable populations.

“As a result of the Coronavirus pandemic, a bright light has RECENTLY been shown on the health disparities that have always existed in America,” said Dr. Oliver Brooks, President of the National Medical Association (NMA). What the world is witnessing is that Black, Hispanic, Native American, Pacific Islander, and Asian patients are severely overrepresented among those who have suffered the morbidity and mortality of COVID-19.”

Data from the 40 states that collect race and ethnicity data show that White Americans are dying from COVID-19 at a rate of 22.7 per 100,000 in the population, whereas African Americans die at a rate 54.6 deaths per 100,000, Hispanic Americans at a rate of 24.9 deaths per 100,000, and Asian Americans at 24.3 deaths per 100,000. Though the data are sparse for Native Americans, in New Mexico they die from the COVID-19 disease at a rate that is eight times that of the white population, and in Arizona they die at a rate that is five times that of all of others in the population. For Native Hawaiians and Pacific Islanders, the available data in ten states show percentages of COVID-19 cases and deaths that are two to three times greater than their percentage of the population.

The letter, addressed also to the head of the Pharmaceutical Researchers and Manufacturers of America, states that the majority of approved drug products come with an FDA disclaimer that there is insufficient availability of data to determine effective response in racial-ethnic minority patients due to lack of participants during testing. That problem is often compounded by a high prevalence of the disease in the same minority patients for which the product is indicated for use. "In these difficult times our most marginalized communities remain at the greatest risk for health disparities. COVID-19 has demonstrated what our communities already know, we need to be as One to end health disparities resulting from non-inclusion and policies of invisibility in healthcare”, said Dr. Brian Thompson, Board Member of the Association of American Indian Physicians (AAIP). “We appreciate FDA efforts to increase diversity and inclusion in all aspects of medical care."

The Alliance, which includes five national physician associations (AAIP, NMA, NHMA, ABC, and the National Council of Asian Pacific Islander Physicians) acknowledged the FDA and its Office of Minority Health and Health Equity for “its leadership and efforts to encourage diversity in clinical trials, especially with COVID-19 exacerbating and highlighting the health disparities that exists in the United States. Now is the time to support programs to increase clinical trial participation of investigators and participants to reflect the current population of the United States,” said Dr. Elena Rios, President & CEO of the National Hispanic Medical Association. In its letter, the Alliance recommended the FDA provide “clear guidance to all sponsors of medical products directed at COVID-19 to assure inclusion that provides the bases for clinically meaningful data to address the needs of a diverse America.”

Members of the Alliance took note that the path to achieving diverse, reflective clinical trials would take more than regulatory efforts. “An additional focus must be on ensuring that overall or main clinical trial principal investigators are from diverse racial and ethnic groups such as black and Hispanic/LatinX investigators,” Dr. Michelle Albert, President of the Association of Black Cardiologists (ABC). “The latter represents a key upstream component of increasing patient diversity in clinical trials and also improving on current clinical trial strategies and questions."

The group pledged a continuing effort to address disparities in medicine beyond the duration of the pandemic. “Our country is at a critical juncture on how to move confidently and judiciously to address racial injustice, which permeates every aspect of our social and civic lives,” said Dr. Winston Wong, President and Chair of NCAPIP. “Racial equity must also guide our process of evaluating and approving medical therapy for our communities, especially those that have dealt with generations of inequity.”

###

Comments...

Anne-Marie Moukala-Cadet says...
Posted Saturday, June 13, 2020
I’m in practice in Family Medicine in Upstate NY, I’m in primary care. I have an outpatient treatment protocol that I came up with. When I approached the chairman of Family medicine at one of the hospital where I have privileges to consider a clinical trial, I was immediately discouraged that it’s to big of a project and we do not have enough cases here. Anyone Interested in looking at my summary and conducting a clinical trial, please contact me amoukala@gmail.com. Thank you.

National Medical Association | 8403 Colesville Road, Suite 820, Silver Spring, MD 20910 | 202-347-1895